Hubei Guangji Pharmaceutical Co Ltd

Guangji Pharmaceutical released its 2026 half-year report on August 27. The company achieved operating revenue of 312 million yuan, up 9.71 percent year on year. Net loss attributable to shareholders was 57.9451 million yuan, compared with a loss of 75.5151 million yuan in the same period last year, narrowing the loss. During the reporting period, sales volume of the company's main product, vitamin B2, increased significantly compared with the same period last year.

Guangji Pharmaceutical released its 2026 interim report. First-half operating revenue was 312 million yuan, up 9.7 percent year on year. Net loss attributable to the parent was 57.95 million yuan, narrowing from a loss of 75.52 million yuan in the same period last year. Net loss attributable to the parent after deducting non-recurring items was 65.59 million yuan, down from a loss of 78.41 million yuan a year earlier. Net operating cash flow was 43.73 million yuan, up 73.1 percent year on year. Earnings per share were negative 0.1684 yuan. In the second quarter, operating revenue was 149 million yuan, up 9.6 percent year on year. Net loss attributable to the parent was 26.3 million yuan, narrowing from a loss of 39.25 million yuan in the same period last year. Net loss attributable to the parent after deducting non-recurring items was 32.9 million yuan, down from a loss of 41.16 million yuan a year earlier. As of the end of the second quarter, total assets were 2.178 billion yuan, down 5.8 percent from the end of the previous year. Net assets attributable to the parent were 598 million yuan, down 8.6 percent from the end of the previous year. The company's main business is the research, development, production and sale of vitamin raw material products. Its subsidiary Jikang focuses on pharmaceutical preparations and is gradually improving profitability.

Guangji Pharmaceutical announced that it plans to issue up to 94.94 million A-shares to its controlling shareholder, Changjiang Industry Investment Group, raising total proceeds of up to 600 million yuan. Changjiang Industry Investment Group will subscribe to all shares in cash. The raised funds will be used to repay borrowings and replenish working capital. As of March 31, 2026, the company's asset-liability ratio was 74.12 percent. This private placement aims to reduce reliance on debt financing and optimize the capital structure. In the first quarter of 2026, the company achieved revenue of 163 million yuan, with a net loss attributable to the parent company of 31.64 million yuan.